Literature DB >> 23940288

Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival.

Jessica Chubak1, Denise M Boudreau, Heidi S Wirtz, Barbara McKnight, Noel S Weiss.   

Abstract

Studies of the effects of exposures after cancer diagnosis on cancer recurrence and survival can provide important information to the growing group of cancer survivors. Observational studies that address this issue generally fall into one of two categories: 1) those using health plan automated data that contain "continuous" information on exposures, such as studies that use pharmacy records; and 2) survey or interview studies that collect information directly from patients once or periodically postdiagnosis. Reverse causation, confounding, selection bias, and information bias are common in observational studies of cancer outcomes in relation to exposures after cancer diagnosis. We describe these biases, focusing on sources of bias specific to these types of studies, and we discuss approaches for reducing them. Attention to known challenges in epidemiologic research is critical for the validity of studies of postdiagnosis exposures and cancer outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23940288      PMCID: PMC3787908          DOI: 10.1093/jnci/djt211

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  Marginal structural models and causal inference in epidemiology.

Authors:  J M Robins; M A Hernán; B Brumback
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.

Authors:  E S O'Meara; M A Rossing; J R Daling; J G Elmore; W E Barlow; N S Weiss
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

3.  A structural approach to selection bias.

Authors:  Miguel A Hernán; Sonia Hernández-Díaz; James M Robins
Journal:  Epidemiology       Date:  2004-09       Impact factor: 4.822

4.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

5.  Tutorial in biostatistics: competing risks and multi-state models.

Authors:  H Putter; M Fiocco; R B Geskus
Journal:  Stat Med       Date:  2007-05-20       Impact factor: 2.373

6.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

Review 7.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.

Authors:  N E Breslow; N E Day
Journal:  IARC Sci Publ       Date:  1987

8.  NSAID use and survival after breast cancer diagnosis in post-menopausal women.

Authors:  Cindy K Blair; Carol Sweeney; Kristin E Anderson; Aaron R Folsom
Journal:  Breast Cancer Res Treat       Date:  2006-07-06       Impact factor: 4.872

9.  Induction and latent periods.

Authors:  K J Rothman
Journal:  Am J Epidemiol       Date:  1981-08       Impact factor: 4.897

10.  Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.

Authors:  Michael J Hassett; Debra P Ritzwoller; Nathan Taback; Nikki Carroll; Angel M Cronin; Gladys V Ting; Deb Schrag; Joan L Warren; Mark C Hornbrook; Jane C Weeks
Journal:  Med Care       Date:  2014-10       Impact factor: 2.983

View more
  43 in total

1.  Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.

Authors:  Elizabeth M Garry; John B Buse; Jennifer L Lund; Virginia Pate; Til Stürmer
Journal:  Diabetes Obes Metab       Date:  2017-08-08       Impact factor: 6.577

2.  Breast cancer recurrence in relation to antidepressant use.

Authors:  Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau
Journal:  Cancer Causes Control       Date:  2015-10-30       Impact factor: 2.506

3.  Statin use and breast cancer survival: a nationwide cohort study in Scotland.

Authors:  Úna C Mc Menamin; Liam J Murray; Carmel M Hughes; Chris R Cardwell
Journal:  BMC Cancer       Date:  2016-08-04       Impact factor: 4.430

4.  Associations among statins, preventive care, and prostate cancer mortality.

Authors:  Abhishek Kumar; Paul Riviere; Elaine Luterstein; Vinit Nalawade; Lucas Vitzthum; Reith R Sarkar; Alex K Bryant; John P Einck; Arno J Mundt; James D Murphy; Brent S Rose
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-06       Impact factor: 5.554

Review 5.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

6.  Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.

Authors:  Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau
Journal:  Am J Epidemiol       Date:  2017-04-15       Impact factor: 4.897

7.  Lipid-lowering medication use and cancer-specific survival among endometrial or lung cancer patients: an Australian nationwide cohort study.

Authors:  Jia-Li Feng; Xiwen Qin
Journal:  Eur J Clin Pharmacol       Date:  2020-10-08       Impact factor: 2.953

8.  Statins Are Associated With Reduced Mortality in Multiple Myeloma.

Authors:  Kristen Marie Sanfilippo; Jesse Keller; Brian F Gage; Suhong Luo; Tzu-Fei Wang; Gerald Moskowitz; Jason Gumbel; Brandon Blue; Katiuscia O'Brian; Kenneth R Carson
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 9.  Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis.

Authors:  Mary C Playdon; Michael B Bracken; Tara B Sanft; Jennifer A Ligibel; Maura Harrigan; Melinda L Irwin
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

10.  Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study.

Authors:  Thomas I Barron; Evelyn M Flahavan; Linda Sharp; Kathleen Bennett; Kala Visvanathan
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.